<DOC>
	<DOCNO>NCT01839773</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety DHP107 ( Oral paclitaxel ) comparison Taxol® ( IV paclitaxel ) Patients With Metastatic Recurrent Gastric Cancer After Failure 1st Line Chemotherapy With Fluoropyrimidine +/- Platinum .</brief_summary>
	<brief_title>A Phase 3 Study Compare Efficacy Safety DHP107 Versus Taxol® Patients With Metastatic Recurrent Gastric Cancer After Failure First-line Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . ≥20 year age 2 . Histologically cytologically confirm unresectable , recurrent metastatic gastric cancer 3 . Failure first line therapy fluoropyrimidine +/ platinum metastatic recurrent disease . ( Adjuvant chemotherapy consider first line chemotherapy unless recurrence develop within 6 month completion adjuvant therapy . ) 4 . Adequate bone marrow , liver renal function 5 . INR ≤ 2.0 6 . ECOG performance status ≤ 2 7 . Neuropathy grade ≤ 1 8 . Life expectancy least 3 month 9 . Measurable lesion accord RECIST version 1.1 CT scan 10 . Written inform consent 11 . Patients child bearing age agree usage adequate contraception registration study , participation period 90 day end treatment . Female child bear age show negative urin pregnancy test within 7 day begin start administration . Amenorrhea status sustain least 12 month consider nonpregnant case postmenstrual woman . 1 . Major infectious disease , neurological disorder , bowel obstruction . 2 . Patients CNS metastasis ( confirm brain imaging symptom ) 3 . Patient diagnose another cancer type ( except nonmelanoma skin cancer , cervical cancer , cancer recur metastasize 5 year consider complete remission register ) 4 . Patient receive radiation therapy within past 2 week major surgery include organ resection within past 4 week random assignment date 5 . Patient history failure taxane chemotherapy 6 . Patient need chronic concomitant use P glycoprotein , immune suppressor , proton pump inhibitor , H2receptor antagonist period clinical trial 7 . Chronic treatment use steroid ( except oral , local injection , externally apply ) immune suppressor 8 . Patient myocardial infarction , congestive heart failure , arrhythmia show abrupt change ECG , severe unstable angina , serious heart disease 9 . Patient serious internal disease ( chronic obstructive chronic inhibitory lung disease include shortness breathe rest due reason , uncontrollable diabetes hypertension ) 10 . History abuse drug alcohol within 3 month 11 . Lactating pregnant woman , patient ( spouse ) intension use , use effective mean contraception 12 . Patient suspect problem bile acid secretion 13 . Patient active gastrointestinal bleeding , take oral anti vitamine K ( With exception low dose Warfarin acetylsalicylic acide INR≤2.0 ) 14 . History serious hypersensitive reaction main ingredient excipient investigational drug 15 . History seropositive HIV ( HIV test prerequisite ) . 16 . Patients gastrointestinal dysfunction enteral feed 17 . Other patient deem inadequate participate clinical trial investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Stomach Neoplasms</keyword>
	<keyword>Cancer Stomach</keyword>
	<keyword>Gastric Cancer</keyword>
	<keyword>Gastric Neoplasms</keyword>
	<keyword>Neoplasms , Gastric</keyword>
	<keyword>Neoplasms , Stomach</keyword>
	<keyword>Stomach Cancer</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>Taxol</keyword>
</DOC>